The SPDR S&P Biotech ETF (NYSEArca: XBI), the second-largest biotech ETF by assets, and theMarket Vectors Biotech ETF (NYSEArca: BBH) gained 11.7% and 11%, respectively, last month. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF, added 10.5%. Like BBH, IBB is heavily allocated to the largest biotech names such as Amegen (NasdaqGS: AMGN) and Biogen (NasdaqGS: BIIB) while XBI is an equal-weight ETF with more exposure to smaller biotech firms. [About That Biotech ETF Bubble]

Even with the August gains, some investors are cautiously approaching biotech ETFs. Combined, IBB, FBT, BBH and XBI added about $180 million in new assets last month, a fraction of the $752.8 million hauled in by the Health Care Select Sector SPDR (NYSEArca: XLV).

Although the quartet finished slightly lower, BBH, FBT, IBB and PBE all made new all-time highs again on Monday.

iShares Nasdaq Biotechnology ETF

ETF Trends editorial team contributed to this post.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.